文献速递神经肿瘤

抑制NAMPT靶向胶质瘤异质性通过线粒体氧化应激

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
PubMed 文献 · Neuro Oncol · 2022-01-01

本文探讨抑制NAD补救合成途径限速酶NAMPT对遗传异质性胶质瘤的作用。体外及离体实验使用KPT-9274抑制NAMPT,导致NAD水平下降、抑制增殖并诱导凋亡,效应由线粒体功能障碍和氧化应激介导,且不依赖基因型、IDH或MGMT状态。对正常星形胶质细胞影响小,非荷瘤小鼠无明显毒性。

要点

  • NAMPT在胶质瘤中高表达,可作为肿瘤特异性代谢靶点。
  • KPT-9274抑制NAMPT降低NAD水平,抑制增殖并诱导凋亡。
  • 效应不依赖IDH状态或MGMT启动子甲基化状态。

核心结论

  • 药理学抑制NAMPT通过激活线粒体功能障碍有效靶向遗传异质性胶质瘤。
  • 临床前结果支持靶向NAMPT依赖的替代NAD合成途径作为胶质瘤新策略。

研究设计与样本

  • 研究为临床前体外和离体实验,使用遗传异质性胶质瘤细胞系、胶质瘤干细胞样细胞及小鼠和人离体器官型胶质瘤切片培养模型。

主要发现

  • KPT-9274抑制NAMPT降低NAD水平及相关下游代谢物,抑制增殖并诱导凋亡。
  • 效应由线粒体功能障碍、DNA损伤和氧化应激增加介导,导致胶质瘤干细胞样细胞凋亡,不依赖基因型、IDH状态或MGMT启动子甲基化状态。
  • NAMPT抑制对正常人类星形胶质细胞体外影响极小,非荷瘤小鼠体内无明显毒性。

关键数值与推荐

  • 使用高特异性NAMPT抑制剂KPT-9274进行药理学抑制。

临床怎么用

  • NAMPT抑制可能成为针对遗传异质性胶质瘤的临床新策略,尚需进一步临床研究验证。

局限性

  • 研究为临床前体外和离体实验,尚未在患者中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tumor-specific metabolic processes essential for cell survival are promising targets to potentially circumvent intratumoral heterogeneity, a major resistance factor in gliomas. Tumor cells preferentially using nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the salvage pathway for synthesis of NAD, a critical cofactor for diverse biological processes including cellular redox reactions, energy metabolism, and biosynthesis. NAMPT is overexpressed in most malignancies, including gliomas, and can serve as a tumor-specific target. METHODS: Effects of pharmacological inhibition of NAMPT on cellular oxygen consumption rate, extracellular acidification, mitochondrial respiration, cell proliferation, invasion, and survival were assessed through in vitro and ex vivo studies on genetically heterogeneous glioma cell lines, glioma stem-like cells (GSCs), and mouse and human ex vivo organotypic glioma slice culture models. RESULTS: Pharmacological inhibition of the NAD salvage biosynthesis pathway using a highly specific inhibitor, KPT-9274, resulted in the reduction of NAD levels and related downstream metabolites, inhibited proliferation, and induced apoptosis in vitro in cell lines and ex vivo in human glioma tissue. These effects were mediated by mitochondrial dysfunction, DNA damage, and increased oxidative stress leading to apoptosis in GSCs independent of genotype, IDH status, or MGMT promoter methylation status. Conversely, NAMPT inhibition had minimal in vitro effects on normal human astrocytes (NHA) and no apparent in vivo toxicity in non-tumor-bearing mice. CONCLUSIONS: Pharmacological NAMPT inhibition by KPT9274 potently targeted genetically heterogeneous gliomas by activating mitochondrial dysfunction. Our preclinical results provide a rationale for targeting the NAMPT-dependent alternative NAD biosynthesis pathway as a novel clinical strategy against gliomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sharma P, Xu J, Williams K, et al. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. Neuro Oncol. 2022. PMID: 34260721. doi:10.1093/neuonc/noab175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。